A
Alphonse Okwera
Researcher at Makerere University
Publications - 88
Citations - 5588
Alphonse Okwera is an academic researcher from Makerere University. The author has contributed to research in topics: Tuberculosis & Mycobacterium tuberculosis. The author has an hindex of 42, co-authored 88 publications receiving 5187 citations. Previous affiliations of Alphonse Okwera include Case Western Reserve University & Boston Medical Center.
Papers
More filters
Journal ArticleDOI
A Trial of Three Regimens to Prevent Tuberculosis in Ugandan Adults Infected with the Human Immunodeficiency Virus
Christopher C. Whalen,John L. Johnson,Alphonse Okwera,David L. Hom,R. Huebner,Peter Mugyenyi,Roy D. Mugerwa,Jerrold J. Ellner +7 more
TL;DR: A six-month course of isoniazid confers short-term protection against tuberculosis among PPD-positive, HIV-infected adults and multidrug regimens with isoniaZid and rifampin taken for three months also reduce the risk of tuberculosis.
Journal ArticleDOI
Depressed T-Cell Interferon-γ Responses in Pulmonary Tuberculosis: Analysis of Underlying Mechanisms and Modulation with Therapy
Christina S. Hirsch,Zahra Toossi,Catherine Othieno,John L. Johnson,S. K. Schwander,Steven S. Robertson,Robert S. Wallis,K. Edmonds,Alphonse Okwera,Roy D. Mugerwa,Pierre Peters,Jerrold J. Ellner +11 more
TL;DR: The data indicate that the immunosuppression of TB is not only immediate and apparently dependent (at least in part) on Immunosuppressive cytokines early during the course of Mycobacterium TB infection but is also long lasting, presumably relating to a primary abnormality in T-cell function.
Journal ArticleDOI
A study of the safety immunology virology and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis.
Robert S. Wallis,Peter Kyambadde,John L. Johnson,Libby Horter,Rodney Kittle,Monika Pohle,Constance Ducar,Monica Millard,Harriet Mayanja-Kizza,Christopher C. Whalen,Alphonse Okwera +10 more
TL;DR: Etanercept can be safely administered during the initial treatment of pulmonary tuberculosis, and trends towards superior responses to tuberculosis treatment were evident in etanercept-treated subjects in body mass, performance score, number of involved lung zones, cavitary closure, and time to sputum culture conversion.
Journal ArticleDOI
Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda.
Christopher C. Whalen,Peter Nsubuga,Alphonse Okwera,John L. Johnson,David L. Hom,Nelson L. Michael,Roy D. Mugerwa,Jerrold J. Ellner +7 more
TL;DR: The findings from this prospective study indicate that active tuberculosis exerts its greatest effect on survival in the early stages of HIV infection, when there is a reserve capacity of the host immune response.
Journal ArticleDOI
Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults.
John L. Johnson,Alphonse Okwera,David L. Hom,Harriet Mayanja,Cissy Kityo,Peter Nsubuga,J. G. Nakibali,Anita M. Loughlin,Hyun Yun,Peter Mugyenyi,Andrew Vernon,Roy D. Mugerwa,Jerrold J. Ellner,Christopher C. Whalen +13 more
TL;DR: Six months of INH provided short-term protection against tuberculosis in PPD-positive HIV-infected adults; however, benefit was lost within the first year of treatment and sustained protection for up to 3 years was observed in persons receiving 3HR and 3HRZ.